



PC25051A  
Supplemental Information Disclosure Statement  
For Appln. No. 10/765,227

Certificate of Mailing (37 C.F.R. §1.8);  
I hereby certify that this correspondence is being  
deposited with the United States Postal Service as  
**First Class Mail** in an envelope addressed to:  
**Commissioner for Patents, PO Box 1450,**  
**Alexandria, VA 22313-1450, on this 8th day of**  
**June 2004.**

s/ Pamela Hollander  
Pamela Hollander

DFW

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of:  
**Atsuo KUKI, et al.**

Serial No.: **10/765,227**

Confirmation No.: **1726**

Filed: **01/26/2004**

For: **HIV INTEGRASE INHIBITORS,  
PHARMACEUTICAL COMPOSITIONS AND  
METHODS FOR THEIR USE**

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Honorable Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Transmitted herewith are the following documents:

- |  |                  |
|--|------------------|
| 1. Return Receipt Postcard                         | 1 postcard;      |
| 2. Transmittal of Information Disclosure Statement | 2 pages;         |
| 3. PTO.SB/08A (04-03) Form 1449                    | 2 pages;         |
| 4. Copies of cited References                      | 5 References;    |
| 5. Copy of International Search Report             | 9 pages; and     |
| 6. Fee Due   | Deposit Account. |

Respectfully Submitted,

Date: June 8, 2004

Jeffrey H. Tidwell  
Jeffrey H. Tidwell  
Attorney For Applicant  
Registration No. 47,995

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 638-3877  
Fax: (858) 678-8233



PC25051A  
Supplemental Information Disclosure Statement  
For Appl. No. 10/765,227

Certificate of Mailing (37 C.F.R. §1.8):  
I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to:  
Commissioner for Patents, PO Box 1450,  
Alexandria, VA 22313-1450, on this 8th day of June 2004.

s/ Pamela Hollander  
Pamela Hollander

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of:  
**Atsuo KUKI, et al.**

Serial No.: **10/765,227**

Confirmation No.: **1726**

Filed: **01/26/2004**

For: **HIV INTEGRASE INHIBITORS,  
PHARMACEUTICAL COMPOSITIONS AND  
METHODS FOR THEIR USE**

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Honorable Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. § 1.97(b) or 1.97(c)**

**37 CFR § 1.97(b)**

- ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

**37 CFR § 1.97(c)**

- ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of (1) a Final Action under § 1.113; (2) a Notice of Allowance under § 1.311; or (3) an action that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the fee as set forth in § 1.17(p) to Deposit Account Number 500329.

- ☐ Applicant requests that the Examiner consider the following copending applications:

Application Serial No.	Filing Date

- ☐ Copies of these copending applications are enclosed.
- ☐ Applicant hereby requests consideration of the Information Disclosure Statement, USPTO form 1449, submitted herewith. Copies of the cited references, except as noted below, are enclosed.
- ☐ This application is a continuation, divisional or continuation-in-part of Serial No. . Copies of the cited references, if not enclosed, are available in the file of the parent application or parents thereof.
- ☐ This application was filed after June 30, 2003, or entered U.S. national stage under 35 U.S.C. § 371, after June 30, 2003. Copies of U.S. Patents and U.S. Patent Application Publications are not enclosed. (1276 OG 55).
- ☐ Applicant hereby requests consideration of the enclosed International Search Report, which was received in a related international patent application.

The Commissioner is hereby authorized to charge any fee deficiency, including any fee required under 37 C.F.R. § 1.17(p), or credit any overpayment, to Deposit Account Number 500329. A duplicate copy of this form is enclosed.

Respectfully submitted,


Date: June 8, 2004

  
\_\_\_\_\_  
Jeffrey H. Tidwell  
Attorney For Applicant  
Registration No. 47,995

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 638-3877  
Fax: (858) 678-8233

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

## Complete if Known

Application Number	10/765,227
Filing Date	01/26/2004
First Named Inventor	Atsuo KUKI
Art Unit	1726
Examiner Name	Not yet assigned
Attorney Docket Number	PC25051A

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number-Kind Code <sup>2</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	AA	WO 03/033496 A	04.24.2003	Adnan M. MJALLI, et al.		
	AB	WO 99/64420	12.16.1999	Christophe ALAIN, et al.	(English counterpart to EP1086101).	
	AC	EP 0 030 254 A	08.23.1980	Dr. Ulrich, EDER, et al.		
	AD	GB 2 209 032 A	04.26.1989	Charles John Robert HEDGECOCK, et al		
	AE	EP 1 209 158 A	11.18.2000	Dr. Olaf RITZELER, et al.		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.